Clinical Trial Update: Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib for plexiform neurofibromas in NF1 patients (children and adults) has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibromas

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: NF1, Neurofibromatosis | Phase 2 | Status: COMPLETED | Results posted: 2023-05-24